| scholarly article | Q13442814 |
| P50 | author | Daeyoung Roh | Q47447344 |
| Suk Kyoon An | Q59315085 | ||
| Hyun-Sang Cho | Q59806375 | ||
| Young-Chul Jung | Q79704958 | ||
| P2093 | author name string | Chan-Hyung Kim | |
| Jhin-Goo Chang | |||
| P2860 | cites work | Low-dose quetiapine is not a benign sedative-hypnotic agent | Q46390550 |
| Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis | Q47634507 | ||
| Antipsychotic polypharmacy: a needle in a haystack? | Q47967849 | ||
| Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative | Q48102710 | ||
| Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia | Q48685001 | ||
| Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy | Q50112124 | ||
| Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. | Q50786649 | ||
| Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008). | Q50803019 | ||
| Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. | Q50804521 | ||
| High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. | Q51936776 | ||
| Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. | Q51940717 | ||
| Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. | Q51996004 | ||
| Schizophrenia practice guidelines: international survey and comparison. | Q53268023 | ||
| Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries | Q57470966 | ||
| Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics | Q24811190 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Effectiveness of switching from antipsychotic polypharmacy to monotherapy. | Q30542484 | ||
| Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents | Q30913196 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| Chlorpromazine Equivalents Versus Defined Daily Doses: How to Compare Antipsychotic Drug Doses? | Q34277550 | ||
| Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations | Q34941330 | ||
| Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior | Q35175610 | ||
| Dose response and dose equivalence of antipsychotics | Q35810536 | ||
| Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. | Q36057820 | ||
| Safety and tolerability of antipsychotic polypharmacy | Q36062421 | ||
| Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials | Q37137001 | ||
| High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies | Q37156296 | ||
| Polypharmacy with second-generation antipsychotics: a review of evidence | Q37341522 | ||
| Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. | Q37723434 | ||
| Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials | Q37849555 | ||
| A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy | Q40762464 | ||
| Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. | Q43145170 | ||
| Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study | Q43246864 | ||
| Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). | Q46017721 | ||
| P433 | issue | 1 | |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 52-60 | |
| P577 | publication date | 2013-05-13 | |
| P1433 | published in | Australian and New Zealand Journal of Psychiatry | Q4824838 |
| P1476 | title | Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison | |
| P478 | volume | 48 |
| Q42180852 | Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities. |
| Q53169797 | Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. |
| Q44897335 | Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China |
| Q33560808 | Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points |
| Q50540496 | Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. |
| Q48492684 | Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits |
| Q28552825 | Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications |
| Q59791847 | Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality |
| Q39062177 | Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward |
| Q64322632 | Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare |
| Q38972585 | Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country |
| Q55513508 | Risk of weight gain for specific antipsychotic drugs: a meta-analysis. |
| Q35324015 | The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil |
| Q39812513 | Therapeutic Body Wraps in Swiss public adult acute inpatient wards. A retrospective descriptive cohort study. |
| Q38239613 | Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy |
Search more.